What is DSGN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.73B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DSGN?

P/E (TTM) is n/a and 52-week range is $5.28 to $17.25 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DSGN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DSGN?

The company profile lists net income (TTM) near $-74M, EPS (TTM) near $-1.18 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Design Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Carlsbad, California, US, 62.5M shares outstanding, ISIN US25056L1035 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Design Therapeutics Inc

$DSGN

Health Care · Biotechnology

IR Run Scenarios

$11.65

+1.39%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 54 full-time employees. The company went IPO on 2021-03-26. The company is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.

Employees

Website

www.designtx.com/

IPO

2021-03-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)